Publications by authors named "Mark Craighead"

Claim this Profile
Activity of Novel Topoisomerase Inhibitors against and .
Adam O Whelan, Ian Cooper, Nicola Ooi, David Orr, Kevin Blades, Mark Craighead

Antibiotics (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure-activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors.
Amanda Lyons, James Kirkham, Kevin Blades, David Orr, Elizabeth Dauncey, Mark Craighead

Bioorg Med Chem Lett· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teixobactin and Its Analogues: A New Hope in Antibiotic Discovery.
William D Fiers, Mark Craighead, Ishwar Singh

ACS Infect Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
Cédric Charrier, Anne-Marie Salisbury, Victoria J Savage, Thomas Duffy, Emmanuel Moyo, Mark Craighead

Antimicrob Agents Chemother· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae Infection.
Victoria J Savage, Cédric Charrier, Anne-Marie Salisbury, Helen Box, Nathan Chaffer-Malam, Mark W Craighead

Antimicrob Agents Chemother· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure-activity relationships of a novel isothiazolone class of bacterial type II topoisomerase inhibitors.
Ian R Cooper, Andrew J McCarroll, David McGarry, James Kirkham, Mark Pichowicz, Mark Craighead

Bioorg Med Chem Lett· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.
William Arbuckle, James Baker, David Barn, Matilda Bingham, Angus Brown, Mark Craighead

Bioorg Med Chem Lett· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.
Susan E Napier, Jeffrey J Letourneau, Nasrin Ansari, Douglas S Auld, James Baker, Mark Craighead

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.
James Baker, Matilda Bingham, Ruth Blackburn-Munro, Jiaqiang Cai, Mark Craighead

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.
Susan Napier, Grant Wishart, William Arbuckle, James Baker, David Barn, Mark Craighead

Bioorg Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.
Susan E Napier, Jeffrey J Letourneau, Nasrin Ansari, Douglas S Auld, James Baker, Mark Craighead

Bioorg Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effect of glucocorticoid receptor antagonists on glucocorticoid receptor nuclear translocation and DNA binding.
Francesca Spiga, David M Knight, Susanne K Droste, Becky Conway-Campbell, Yvonne Kershaw, Mark Craighead

J Psychopharmacol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist.
Angus R Brown, Michael Bosies, Helen Cameron, John Clark, Angela Cowley, Mark Craighead

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of the V(1b) receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity.
Francesca Spiga, Louise R Harrison, Susan Wood, David M Knight, Cliona P MacSweeney, Mark Craighead

J Endocrinol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of vasopressin 1b receptor blockade on the hypothalamic-pituitary-adrenal response of chronically stressed rats to a heterotypic stressor.
Francesca Spiga, Louise R Harrison, Cliona P MacSweeney, Fiona J Thomson, Mark Craighead

J Endocrinol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a novel and selective V1B receptor antagonist.
Mark Craighead, Rachel Milne, Leigh Campbell-Wan, Lynn Watson, Jeremy Presland

Prog Brain Res· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiglucocorticoids, neurogenesis and depression.
Carlos P Fitzsimons, Lenneke W A van Hooijdonk, John A Morrow, Bernard W M M Peeters, Niall Hamilton, Mark Craighead

Mini Rev Med Chem· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucocorticoid receptor antagonism augments fluoxetine-induced downregulation of the 5-HT transporter.
Daniel Anthony Johnson, Colin David Ingram, Emma Jane Grant, Mark Craighead, Sarah Elizabeth Gartside

Neuropsychopharmacology· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovative approaches for the treatment of depression: targeting the HPA axis.
Fiona Thomson, Mark Craighead

Neurochem Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the glucocorticoid receptor antagonist Org 34850 on fast and delayed feedback of corticosterone release.
Francesca Spiga, Louise R Harrison, Susan A Wood, Cliona P MacSweeney, Fiona J Thomson, Mark Craighead

J Endocrinol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis